In conjunction with the acquisition, and disclosed separately today, Genospectra closed a $12.2-million financing with Sigma-Aldrich and certain existing investors and affiliates of both companies.
Panomics, which is located in
The combined company, which will be called Panomics, will play in markets including cell signaling, RNAi-mediated gene silencing and high performance assays, clinical biomarker discovery, and predictive toxicology.
Genospectra CEO Frank Witney will be CEO of the new company and Jason Li, founder and CEO of Panomics, will be chief operating officer.
The new company will be headquartered at Genospectra's existing facilities in